Reviewing Palisade Bio (NASDAQ:PALI) and Spero Therapeutics (NASDAQ:SPRO)

Spero Therapeutics (NASDAQ:SPRO) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Earnings & Valuation

This table compares Spero Therapeutics and Palisade Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80 million	0.87	$8.57 million	$0.11	9.09
Palisade Bio	$250,000.00	803.17	-$16.78 million	($0.48)	-2.33

Spero Therapeutics has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Spero Therapeutics and Palisade Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0	3	2	0	2.40
Palisade Bio	1	0	7	2	3.00

Spero Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 500.06%. Palisade Bio has a consensus target price of $9.00, suggesting a potential upside of 703.57%. Given Palisade Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Spero Therapeutics.

Institutional & Insider Ownership

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spero Therapeutics and Palisade Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	10.54%	9.11%
Palisade Bio	N/A	-35.60%	-34.04%

Risk & Volatility

Spero Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Summary

Spero Therapeutics beats Palisade Bio on 9 of the 15 factors compared between the two stocks.

About Spero Therapeutics

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.